Argentarii LLC Takes $271,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Argentarii LLC acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 7,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $271,000.

A number of other hedge funds have also made changes to their positions in SUPN. QRG Capital Management Inc. grew its stake in Supernus Pharmaceuticals by 6.2% during the 3rd quarter. QRG Capital Management Inc. now owns 16,801 shares of the specialty pharmaceutical company’s stock worth $524,000 after buying an additional 986 shares during the last quarter. Principal Financial Group Inc. grew its stake in Supernus Pharmaceuticals by 5.4% during the 3rd quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company’s stock worth $8,899,000 after buying an additional 14,566 shares during the last quarter. Assetmark Inc. grew its stake in Supernus Pharmaceuticals by 2.8% during the 3rd quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after buying an additional 908 shares during the last quarter. Meritage Portfolio Management grew its stake in Supernus Pharmaceuticals by 10.8% during the 3rd quarter. Meritage Portfolio Management now owns 44,295 shares of the specialty pharmaceutical company’s stock worth $1,381,000 after buying an additional 4,328 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D purchased a new position in Supernus Pharmaceuticals during the 3rd quarter worth approximately $1,774,000.

Supernus Pharmaceuticals Trading Up 0.8 %

Supernus Pharmaceuticals stock opened at $32.07 on Monday. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The stock has a 50 day moving average of $36.70 and a two-hundred day moving average of $35.28. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 29.97 and a beta of 0.83.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.